- Datum18.11.2025
- Uhrzeit17:00 - 18:00 Uhr
- Veranstalter
stock3
AbbVie Inc. Aktie
Verkaufen
Kaufen
AbbVie Inc. Chart
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
AbbVie Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| NYSE | VK | |||||
| L&S | VK | |||||
| Tradegate | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (NYSE)
0,08 %
Intraday
6,07 %
1 Woche
1,46 %
1 Monat
30,82 %
Seit Jahresbeginn
37,04 %
1 Jahr
53,20 %
3 Jahre
134,72 %
5 Jahre
288,35 %
10 Jahre
Passender Service zu AbbVie Inc.
Webinar zu AbbVie Inc.
Kursinformationen (NYSE)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)163,810-244,810
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von AbbVie Inc.
| Ex-Datum | Fiskaljahr | Dividende | Rendite |
|---|---|---|---|
| - | 2028 (e) | ||
| - | 2027 (e) | ||
| - | 2026 (e) | ||
| 16.01.2026 | 2026 | 1,73 $ | 0,74 % |
| - | 2025 (e) | ||
| 15.10.2025 | 2025 | 1,64 $ | 0,72 % |
| 15.07.2025 | 2025 | 1,64 $ | 0,86 % |
| 15.04.2025 | 2025 | 1,64 $ | 0,92 % |
| 15.01.2025 | 2025 | 1,64 $ | 0,93 % |
| 15.10.2024 | 2024 | 1,55 $ | 0,79 % |
| 15.07.2024 | 2024 | 1,55 $ | 0,91 % |
| 12.04.2024 | 2024 | 1,55 $ | 0,93 % |
| 12.01.2024 | 2024 | 1,55 $ | 0,95 % |
| 12.10.2023 | 2023 | 1,48 $ | 0,99 % |
| 12.01.2023 | 2023 | 1,48 $ | 0,94 % |
| 13.04.2023 | 2023 | 1,48 $ | 0,91 % |
| 13.07.2023 | 2023 | 1,48 $ | 1,10 % |
| 13.10.2022 | 2022 | 1,41 $ | 1,01 % |
| 14.07.2022 | 2022 | 1,41 $ | 0,93 % |
| 13.04.2022 | 2022 | 1,41 $ | 0,84 % |
| 13.01.2022 | 2022 | 1,41 $ | 1,03 % |
| 14.10.2021 | 2021 | 1,30 $ | 1,20 % |
| 14.07.2021 | 2021 | 1,30 $ | 1,10 % |
| 14.04.2021 | 2021 | 1,30 $ | 1,20 % |
| 14.01.2021 | 2021 | 1,30 $ | 1,16 % |
| 14.01.2020 | 2020 | 1,18 $ | 1,33 % |
| 14.10.2020 | 2020 | 1,18 $ | 1,34 % |
| 14.07.2020 | 2020 | 1,18 $ | 1,21 % |
| 14.04.2020 | 2020 | 1,18 $ | 1,47 % |
| 11.10.2019 | 2019 | 1,07 $ | 1,44 % |
| 12.07.2019 | 2019 | 1,07 $ | 1,50 % |
| 12.04.2019 | 2019 | 1,07 $ | 1,31 % |
| 14.01.2019 | 2019 | 1,07 $ | 1,21 % |
| 12.10.2018 | 2018 | 0,96 $ | 1,06 % |
| 12.07.2018 | 2018 | 0,96 $ | 1,01 % |
| 12.04.2018 | 2018 | 0,96 $ | 1,03 % |
| 11.01.2018 | 2018 | 0,71 $ | 0,71 % |
| 12.10.2017 | 2017 | 0,64 $ | 0,69 % |
| 12.07.2017 | 2017 | 0,64 $ | 0,89 % |
| 11.04.2017 | 2017 | 0,64 $ | 0,99 % |
| 11.01.2017 | 2017 | 0,64 $ | 1,00 % |
| 13.07.2016 | 2016 | 0,57 $ | 0,87 % |
| 13.01.2016 | 2016 | 0,57 $ | 1,04 % |
| 13.04.2016 | 2016 | 0,57 $ | 0,95 % |
| 12.10.2016 | 2016 | 0,57 $ | 0,91 % |
| 13.10.2015 | 2015 | 0,51 $ | 0,91 % |
| 13.07.2015 | 2015 | 0,51 $ | 0,74 % |
| 13.04.2015 | 2015 | 0,51 $ | 0,82 % |
| 13.01.2015 | 2015 | 0,49 $ | 0,75 % |
| 10.10.2014 | 2014 | 0,42 $ | 0,74 % |
| 11.07.2014 | 2014 | 0,42 $ | 0,75 % |
| 11.04.2014 | 2014 | 0,42 $ | 0,89 % |
| 13.01.2014 | 2014 | 0,40 $ | 0,79 % |
| 11.01.2013 | 2013 | 0,40 $ | 1,18 % |
| 10.10.2013 | 2013 | 0,40 $ | 0,89 % |
| 11.07.2013 | 2013 | 0,40 $ | 0,91 % |
| 11.04.2013 | 2013 | 0,40 $ | 0,92 % |
Termine von AbbVie Inc.
- Feb4AbbVie Inc.Q4 2025 Earnings Release
- Apr24AbbVie Inc.Q1 2026 Earnings Release
- Jul24AbbVie Inc.Q2 2026 Earnings Release
Beschreibung
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
